SG11202007317XA - Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent - Google Patents

Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Info

Publication number
SG11202007317XA
SG11202007317XA SG11202007317XA SG11202007317XA SG11202007317XA SG 11202007317X A SG11202007317X A SG 11202007317XA SG 11202007317X A SG11202007317X A SG 11202007317XA SG 11202007317X A SG11202007317X A SG 11202007317XA SG 11202007317X A SG11202007317X A SG 11202007317XA
Authority
SG
Singapore
Prior art keywords
platinum
cancer therapy
anticancer agent
macrocyclic ring
based anticancer
Prior art date
Application number
SG11202007317XA
Inventor
Jeffery L Keene
Dennis P Riley
Robert A Beardsley
Michael Dean Story
Kranti Ashok Mapuskar
Spitz, Jr
Bryan G Allen
Andrew Blake Davis
Orozco Diana Zepeda
Original Assignee
Galera Labs Llc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs Llc, Univ Texas filed Critical Galera Labs Llc
Publication of SG11202007317XA publication Critical patent/SG11202007317XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007317XA 2018-01-31 2019-01-31 Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent SG11202007317XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624250P 2018-01-31 2018-01-31
PCT/US2019/016071 WO2019152661A1 (en) 2018-01-31 2019-01-31 Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Publications (1)

Publication Number Publication Date
SG11202007317XA true SG11202007317XA (en) 2020-08-28

Family

ID=67479466

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007317XA SG11202007317XA (en) 2018-01-31 2019-01-31 Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Country Status (14)

Country Link
US (1) US20210338686A1 (en)
EP (1) EP3746085A4 (en)
JP (2) JP2021512110A (en)
KR (1) KR20200118823A (en)
CN (1) CN111902147A (en)
AU (1) AU2019215032A1 (en)
BR (1) BR112020015520A2 (en)
CA (1) CA3090129A1 (en)
EA (1) EA202091832A1 (en)
IL (1) IL276407A (en)
MX (1) MX2020008028A (en)
PH (1) PH12020551176A1 (en)
SG (1) SG11202007317XA (en)
WO (1) WO2019152661A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2056675T1 (en) 2006-10-12 2019-08-30 Galera Labs, Llc Methods of treating oral mucositis
EP2760874A4 (en) 2011-09-26 2015-04-08 Galera Therapeutics Llc Methods for treatment of diseases
JP2019131508A (en) * 2018-01-31 2019-08-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (en) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
WO1993023555A1 (en) 1992-05-21 1993-11-25 The Penn State Research Foundation Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696458B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
FR2696463B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696461B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New derivatives of taxol analogs, their preparation and compositions containing them.
FR2696464B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New esterification process for baccatin III and 10-deacetyl baccatin III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
SK182599A3 (en) 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
WO2005097123A2 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
WO2006078713A2 (en) * 2005-01-19 2006-07-27 Metaphore Pharmaceuticals, Inc. Methotrexate combinations for treating inflammatory diseases
WO2007139897A1 (en) * 2006-05-23 2007-12-06 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
SI2056675T1 (en) * 2006-10-12 2019-08-30 Galera Labs, Llc Methods of treating oral mucositis
EP2296645B1 (en) * 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc Methods for treatment of diseases
EP3452060A4 (en) * 2016-05-03 2020-01-01 Galera Labs, LLC Combination therapy for cancer treatment

Also Published As

Publication number Publication date
EP3746085A4 (en) 2022-03-09
PH12020551176A1 (en) 2021-06-07
IL276407A (en) 2020-09-30
EP3746085A1 (en) 2020-12-09
BR112020015520A2 (en) 2021-02-02
US20210338686A1 (en) 2021-11-04
EA202091832A1 (en) 2021-01-11
CA3090129A1 (en) 2019-08-08
JP2021512110A (en) 2021-05-13
KR20200118823A (en) 2020-10-16
JP2024054295A (en) 2024-04-16
MX2020008028A (en) 2020-12-11
AU2019215032A1 (en) 2020-09-10
WO2019152661A1 (en) 2019-08-08
CN111902147A (en) 2020-11-06

Similar Documents

Publication Publication Date Title
IL276407A (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
EP3600452A4 (en) Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
IL271888A (en) Therapeutic and diagnostic methods for cancer
EP3883610A4 (en) Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
EP3638367A4 (en) Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3206987A4 (en) Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
IL274246A (en) Diagnostic and therapeutic methods for cancer
IL271946A (en) Combination cancer therapy
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
EP3506907A4 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
EP3169312A4 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
PL3423087T3 (en) Combination therapy against cancer
IL273071A (en) Diagnostic and therapeutic methods for cancer
EP3307329A4 (en) Cancer treatment and diagnosis
EP3600393A4 (en) Combination therapy for the treatment of solid and hematological cancers
EP3180000A4 (en) Cancer diagnosis and therapy
EP3658172A4 (en) Treating cancer by blocking the interaction of tim-3 and its ligand
EP3137107A4 (en) Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3609510A4 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
HK1245096A1 (en) Cell therapeutic agent for cancer treatment and combination therapy with same
IL295620B1 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3706746A4 (en) A combination therapy with apatinib for the treatment of cancer
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab